Stocks · News reference

BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

Sep 2, 2026, 9:43 AMBenzinga Newsdesk

BTIG analyst Mark Massaro reiterates Guardant Health (NASDAQ:GH) with a Buy and maintains $195 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 1, 2026, 5:50 PMBenzinga Newsdesk
Guardant Health shares are trading higher after the company announced that its Shield blood test for colorectal cancer screening will be covered in Carelon Healthcare Services clinical guidelines.
GH
BenzingaSep 1, 2026, 4:25 PMChandrima Sanyal
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
ARKG CRSP GH IBB IDNA
BenzingaSep 1, 2026, 12:10 PMBenzinga Newsdesk
Carelon Health Services To Cover Guardant Health’s Shield Blood Test
Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersIncreasing total covered Shield lives ages 45 and
GH